Metagenomi Therapeutics (MGX) Long-Term Investments (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Long-Term Investments data on file, last reported at $2.2 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $2.2 million, up 66.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 66.72% YoY), and the FY2025 annual result was $2.2 million, down 37.51% from the prior year.
• Long-Term Investments steadied at $2.2 million in Q1 2026 per MGX's latest filing, from $2.2 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $10.6 million in Q3 2024 and troughed at $1.3 million in Q1 2025.
• A 4-year average of $5.6 million and a median of $5.7 million in 2023 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2025 and 2026: Long-Term Investments tumbled 84.84% in 2025, then soared 66.72% in 2026.
• A 4-year view of Long-Term Investments shows it stood at $8.5 million in 2023, then plunged by 59.55% to $3.4 million in 2024, then slumped by 37.51% to $2.2 million in 2025, then changed by 0.0% to $2.2 million in 2026.
• Business Quant data shows MGX's Long-Term Investments at $2.2 million in Q1 2026, $2.2 million in Q4 2025, and $2.2 million in Q3 2025.